Providing information to the drug discovery sector
LeadDiscovery was founded in 1998 by life scientists to expedite drug discovery and pharmaceutical development. Based on a solid background of experience from within the pharmaceutical research and development sector our aim is to help companies optimize drug discovery and product pipelines through the identification of breaking research and the in depth and expert evaluation of selected therapeutic areas.
At the same time we provide a showcase for pharmaceutical, biotechnology and academic organizations wishing to increase the exposure of their research to the drug development community.
We support the drug discovery and pharmaceutical development community through three key services: DailyUpdates, UpdatesPlus and PharmaReports
- DailyUpdates Launched in 2002 this popular e-mail alert service delivers information on breaking research, new clinical trials, drug development news and recently published market research and pipeline analysis reports. Today's headlines are below. Registration to receive the service is available here
- UpdatesPlus Developed in 2007 as an extension of DailyUpdates, UpdatesPlus provides a monthly in depth analysis of breaking research and development activity in high profile therapeutic areas. Further details can be found here
- PharmaReports We offer a wide range of in depth pharmaceutical reports. Our reports include market research reports and pipeline analyses. You can search our entire portfolio using LeadDiscovery's search engine. Alternatively as we are one of the few information providers that has extensive research and development experience we occupy a unique position of being able to source reports that accurately meet your needs. If we don't have a report that fits your requirements we can produce one through our pharmaceutical consultancy services.
Todays drug discovery and development headlines from across the DailyUpdates network
22nd July 2014
Drug Development News: Trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination demonstrated overall survival benefit compared to vemurafenib; phase III BRAF V600-mutant metastatic melanoma study stopped early
Headlined Journal Article: R848, a Toll-Like Receptors 7 and 8 agonist, a Potential Therapy for Allergic Rhinitis Patients.
Todayâ€™s Featured Pharmaceutical Report: Nuclear Medicine Imaging Devices: Global Market Prospects 2012-2022
Pharmaceutical Training Courses and Meetings: No current events.
LeadDiscovery recommends ClusterMed for faster discovery and automatic organization of PubMed results into categories
PharmaReports: LeadDiscovery offers in depth pharmaceutical reports on selected areas of the pharmaceutical and biotech sector. For a full list of our featured market research reports and pipeline analyses click here